Dr. Martignetti on Next-Generation Sequencing in Fallopian Tube Cancer
John A. Martignetti, MD, PhD, associate professor of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai, network director for the Laboratory for Translational Research at the Western Connecticut Health Network, discusses next-generation sequencing for patients with fallopian tube cancer.
John A. Martignetti, MD, PhD, associate professor of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai, network director for the Laboratory for Translational Research at the Western Connecticut Health Network, discusses next-generation sequencing for patients with fallopian tube cancer.
Next-generation sequencing technology has changed what we can see, explains Martignetti. The level of detail is greatly increased, which has benefitted the treatment landscape of fallopian tube cancer and ovarian cancer.
Circulating tumor DNA can detect cancers earlier, can provide prognostic information, and even has potential for use in screening, states Martignetti.
